Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

muscle damage

5 posts
NNovartis
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

  • 2026-07-04
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
NNovartis
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

  • 2026-06-13
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
NNovartis
Novartis Reports Positive Data for Neuromuscular Disorder Drug
Read More

Novartis Reports Positive Data for Neuromuscular Disorder Drug

  • 2026-06-11
Novartis NVS announced positive data from the biomarker cohort of the FORTITUDE phase I/II study. The FORTITUDE phase…
NNovartis
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
Read More

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

  • 2026-06-11
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
NNovartis
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

  • 2026-06-11
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
Switzerland
www.europesays.com